Stux Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Stux Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	$361K	Sell	5,800 -1,000	-15%	-$60.4K	0.05%	357
2014 Q1	$464K	Sell	6,800 -300	-4%	-$22.1K	0.06%	297
2013 Q4	$499K	Buy	7,100 +100	+1%	+$6.79K	0.06%	271
2013 Q3	$505K	Sell	7,000 -600	-8%	-$39.9K	0.07%	253
2013 Q2	$424K	Buy	+7,600	New	+$474K	0.05%	281

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Stux Capital Management's BMRN Position: Q2 2014 in Review

Stux Capital Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 15% in Q2 2014, selling an estimated $60.4K and leaving 5,800 shares worth $361K. The position accounts for 0.05% of the portfolio, ranked #357.

Stux Capital Management first reported a position in BMRN in Q2 2013 and has held it in 5 quarters since. The position peaked at $505K in Q3 2013. 321 funds tracked by Wall St. Rank hold BMRN as of Q2 2014.

Stux Capital Management held 5,800 shares of BioMarin Pharmaceuticals worth $361K as of Q2 2014.
Stux Capital Management sold 1,000 BioMarin Pharmaceuticals shares in Q2 2014, an estimated $60.4K.
BioMarin Pharmaceuticals made up 0.05% of Stux Capital Management's portfolio in Q2 2014, its #357 holding.
Stux Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 5 quarters since.
Stux Capital Management's BioMarin Pharmaceuticals position peaked at $505K in Q3 2013.
321 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2014.

Based on Stux Capital Management's 13F filing for Q2 2014, filed 14 Jul 2014.